[
    [
        {
            "time": "2023-10-18",
            "original_text": "Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)",
            "features": {
                "keywords": [
                    "IMBRUVICA",
                    "ibrutinib",
                    "RESONATE-2",
                    "Seven Years",
                    "Progression-Free",
                    "Overall Survival",
                    "First-Line",
                    "Chronic Lymphocytic Leukemia",
                    "CLL"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]